Aureka Biotechnologies
Stub Updated Aug 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Aureka Biotechnologies is an AI-native TechBio company developing biological foundation models and closed-loop infrastructure that combines AI, digital biology, and experimental platforms to redesign end-to-end drug discovery. Founded in 2023 by Weian Zhao, the company operates in Laguna Hills, California, with additional operations in Shanghai.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-08-10 | Series B | $100M | Granite Asia | HighLight Capital, MPCi, NRL Capital 123 |
What Investors Say
What Founders Say
Sources
-
PR Newswire, “Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery,” August 10, 2026. Accessed August 30, 2026. https://www.prnewswire.com/news-releases/aureka-biotechnologies-raises-us100-million-series-b-to-build-a-biological-world-model-for-drug-discovery-302847165.html↩
-
BioSpace, “Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery,” August 2026. Accessed August 30, 2026. https://www.biospace.com/press-releases/aureka-biotechnologies-raises-us-100-million-series-b-to-build-a-biological-world-model-for-drug-discovery↩
-
Morningstar / PR Newswire syndication, “Aureka Biotechnologies Raises US$100 Million Series B,” August 10, 2026. Accessed August 30, 2026. https://www.morningstar.com/news/pr-newswire/20260810cn21470/aureka-biotechnologies-raises-us100-million-series-b-to-build-a-biological-world-model-for-drug-discovery↩